TBC1D10B Activators
TBC1 domain family member 10B (TBC1D10B) is a protein encoded by the TBC1D10B gene in humans. Like other members of the TBC (Tre-2/Bub2/Cdc16) domain family, TBC1D10B is characterized by the presence of a TBC domain which typically confers Rab GTPase-activating protein (GAP) activity. Proteins with GAP activity are involved in the regulation of small GTPases, which are molecular switches controlling various cellular processes, including vesicle trafficking, cytoskeletal dynamics, and cell signaling.
The TBC domain acts by catalyzing the conversion of the active GTP-bound form of Rab GTPases to their inactive GDP-bound form, thereby regulating their function. While the specific Rab GTPases that TBC1D10B acts upon may not be comprehensively identified or characterized, the regulation of Rab GTPases by TBC1D10B is expected to play a role in intracellular trafficking pathways and could impact processes such as endocytosis, autophagy, and membrane recycling.The precise biological functions of TBC1D10B in human physiology and pathology remain to be fully elucidated. Studies focusing on TBC1D10B may investigate its expression patterns across different tissues, its role in cellular signaling pathways, and its potential involvement in diseases. Because Rab GTPases are integral to numerous cellular functions, dysregulation of their activity by proteins like TBC1D10B could potentially contribute to a variety of disease states, including cancer, neurological disorders, and metabolic diseases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin indirectly activates TBC1D10B by elevating cAMP levels, which can modulate various signaling pathways that TBC1D10B is involved in. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX, a non-specific phosphodiesterase inhibitor, increases cAMP levels, potentially influencing the activity of TBC1D10B through secondary messengers. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG, a polyphenol in green tea, can modulate signaling pathways related to TBC1D10B, though the exact mechanism of action is not fully understood. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, may indirectly affect TBC1D10B activity by altering downstream signaling pathways, particularly those related to insulin signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, may indirectly influence TBC1D10B through the mTOR signaling pathway, a key regulator in cellular metabolism and growth. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, can indirectly modulate the activity of TBC1D10B through the stress-activated MAPK pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, potentially affects TBC1D10B activity by altering JNK-mediated signaling pathways. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine, an AKT inhibitor, can indirectly modulate TBC1D10B activity by influencing the PI3K/AKT signaling pathway. | ||||||
Wnt Agonist | 853220-52-7 | sc-222416 sc-222416A | 5 mg 25 mg | $154.00 $597.00 | 23 | |
This chemical activates the Wnt signaling pathway, which may indirectly influence TBC1D10B activity. | ||||||